Medical management of Cushing disease.

Bradley A. Gross, Stefan A. Mindea, Anthony J. Pick, James P. Chandler, H. Hunt Batjer

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although transsphenoidal excision of the adrenocorticotropic hormone (ACTH)-producing neoplasm is often the treatment of choice in patients with Cushing disease, medical management is itself a useful preoperative temporizing measure, an option for long-term management in nonsurgical candidates, and an option for patients in whom surgery and/or radiotherapy have failed. Three pathophysiologically based approaches exist in the research literature--neuro-modulation to limit ACTH levels, adrenal enzyme inhibition, and glucocorticoid receptor antagonism. Unfortunately, the neuromodulatory approach involving agents such as bromocriptine, cyproheptadine, octreotide, and valproate has yielded only suboptimal results. Glucocorticoid receptor antagonism remains in its infancy but may overall be limited by side effects and a resultant increase in ACTH and cortisol levels. Adrenal enzyme inhibitors, however, offer substantial future promise in the management of Cushing disease but are limited by the potential need to use them indefinitely and by dose-tolerance effects. Although etomidate is a potential intravenous alternative for acute cortisol level control, ketoconazole has shown efficacy in the long-term treatment of patients with the disease. Metyrapone and/or aminoglutethimide can be added to ketoconazole if additional control is needed. If success is still not achieved, the potent adrenolytic agent often used for adrenocortical carcinomas, mitotane, is another alternative.

Original languageEnglish (US)
JournalNeurosurgical Focus
Volume23
Issue number3
StatePublished - 2007

Fingerprint

Pituitary ACTH Hypersecretion
Adrenocorticotropic Hormone
Ketoconazole
Glucocorticoid Receptors
Hydrocortisone
Mitotane
Aminoglutethimide
Etomidate
Adrenocortical Carcinoma
Cyproheptadine
Metyrapone
Adrenergic Antagonists
Octreotide
Bromocriptine
Valproic Acid
Enzyme Inhibitors
Disease Management
Radiotherapy
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Gross, B. A., Mindea, S. A., Pick, A. J., Chandler, J. P., & Batjer, H. H. (2007). Medical management of Cushing disease. Neurosurgical Focus, 23(3).

Medical management of Cushing disease. / Gross, Bradley A.; Mindea, Stefan A.; Pick, Anthony J.; Chandler, James P.; Batjer, H. Hunt.

In: Neurosurgical Focus, Vol. 23, No. 3, 2007.

Research output: Contribution to journalArticle

Gross, BA, Mindea, SA, Pick, AJ, Chandler, JP & Batjer, HH 2007, 'Medical management of Cushing disease.', Neurosurgical Focus, vol. 23, no. 3.
Gross BA, Mindea SA, Pick AJ, Chandler JP, Batjer HH. Medical management of Cushing disease. Neurosurgical Focus. 2007;23(3).
Gross, Bradley A. ; Mindea, Stefan A. ; Pick, Anthony J. ; Chandler, James P. ; Batjer, H. Hunt. / Medical management of Cushing disease. In: Neurosurgical Focus. 2007 ; Vol. 23, No. 3.
@article{4baa136a53894602ab5d785f61e400cc,
title = "Medical management of Cushing disease.",
abstract = "Although transsphenoidal excision of the adrenocorticotropic hormone (ACTH)-producing neoplasm is often the treatment of choice in patients with Cushing disease, medical management is itself a useful preoperative temporizing measure, an option for long-term management in nonsurgical candidates, and an option for patients in whom surgery and/or radiotherapy have failed. Three pathophysiologically based approaches exist in the research literature--neuro-modulation to limit ACTH levels, adrenal enzyme inhibition, and glucocorticoid receptor antagonism. Unfortunately, the neuromodulatory approach involving agents such as bromocriptine, cyproheptadine, octreotide, and valproate has yielded only suboptimal results. Glucocorticoid receptor antagonism remains in its infancy but may overall be limited by side effects and a resultant increase in ACTH and cortisol levels. Adrenal enzyme inhibitors, however, offer substantial future promise in the management of Cushing disease but are limited by the potential need to use them indefinitely and by dose-tolerance effects. Although etomidate is a potential intravenous alternative for acute cortisol level control, ketoconazole has shown efficacy in the long-term treatment of patients with the disease. Metyrapone and/or aminoglutethimide can be added to ketoconazole if additional control is needed. If success is still not achieved, the potent adrenolytic agent often used for adrenocortical carcinomas, mitotane, is another alternative.",
author = "Gross, {Bradley A.} and Mindea, {Stefan A.} and Pick, {Anthony J.} and Chandler, {James P.} and Batjer, {H. Hunt}",
year = "2007",
language = "English (US)",
volume = "23",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Medical management of Cushing disease.

AU - Gross, Bradley A.

AU - Mindea, Stefan A.

AU - Pick, Anthony J.

AU - Chandler, James P.

AU - Batjer, H. Hunt

PY - 2007

Y1 - 2007

N2 - Although transsphenoidal excision of the adrenocorticotropic hormone (ACTH)-producing neoplasm is often the treatment of choice in patients with Cushing disease, medical management is itself a useful preoperative temporizing measure, an option for long-term management in nonsurgical candidates, and an option for patients in whom surgery and/or radiotherapy have failed. Three pathophysiologically based approaches exist in the research literature--neuro-modulation to limit ACTH levels, adrenal enzyme inhibition, and glucocorticoid receptor antagonism. Unfortunately, the neuromodulatory approach involving agents such as bromocriptine, cyproheptadine, octreotide, and valproate has yielded only suboptimal results. Glucocorticoid receptor antagonism remains in its infancy but may overall be limited by side effects and a resultant increase in ACTH and cortisol levels. Adrenal enzyme inhibitors, however, offer substantial future promise in the management of Cushing disease but are limited by the potential need to use them indefinitely and by dose-tolerance effects. Although etomidate is a potential intravenous alternative for acute cortisol level control, ketoconazole has shown efficacy in the long-term treatment of patients with the disease. Metyrapone and/or aminoglutethimide can be added to ketoconazole if additional control is needed. If success is still not achieved, the potent adrenolytic agent often used for adrenocortical carcinomas, mitotane, is another alternative.

AB - Although transsphenoidal excision of the adrenocorticotropic hormone (ACTH)-producing neoplasm is often the treatment of choice in patients with Cushing disease, medical management is itself a useful preoperative temporizing measure, an option for long-term management in nonsurgical candidates, and an option for patients in whom surgery and/or radiotherapy have failed. Three pathophysiologically based approaches exist in the research literature--neuro-modulation to limit ACTH levels, adrenal enzyme inhibition, and glucocorticoid receptor antagonism. Unfortunately, the neuromodulatory approach involving agents such as bromocriptine, cyproheptadine, octreotide, and valproate has yielded only suboptimal results. Glucocorticoid receptor antagonism remains in its infancy but may overall be limited by side effects and a resultant increase in ACTH and cortisol levels. Adrenal enzyme inhibitors, however, offer substantial future promise in the management of Cushing disease but are limited by the potential need to use them indefinitely and by dose-tolerance effects. Although etomidate is a potential intravenous alternative for acute cortisol level control, ketoconazole has shown efficacy in the long-term treatment of patients with the disease. Metyrapone and/or aminoglutethimide can be added to ketoconazole if additional control is needed. If success is still not achieved, the potent adrenolytic agent often used for adrenocortical carcinomas, mitotane, is another alternative.

UR - http://www.scopus.com/inward/record.url?scp=38449090257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449090257&partnerID=8YFLogxK

M3 - Article

VL - 23

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 3

ER -